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Abstract
Background: Lipids are implicated in the pathogenesis of age-related macular degeneration (AMD). The relationship
between systemic lipids and AMD has not been well characterized. The objective was to investigate the relationship
between serum lipids and AMD in older adults using a lipidomic approach.
Methods: In a case-control study, 240 adults, aged ≥66 years, a third each having geographic atrophy, neovascular
AMD, or no signs of AMD, were selected from a population-based sample of participants in the Age Gene/
Environment Susceptibility-Reykjavik Study. The exposure was serum lipids and risk factors for AMD. The outcome was
late AMD, assessed through fundus images taken through dilated pupils using a 45-degree digital camera and grading
for neovascular AMD and geographic atrophy using the modified Wisconsin Age-Related Maculopathy Grading
System.
Results: Of 177 serum lipid species measured, there were no significant differences in serum lipids between controls
and those with geographic atrophy or neovascular AMD, respectively. Adults with neovascular AMD had higher total
serum lysophosphatidylcholine (LPC) (P = 0.004) and serum LPC 18:0 (P = 0.0002) compared to those with geographic
atrophy.
Conclusion: Late AMD was not characterized by alterations in systemic lipids compared with normal controls. These
findings suggest that there may be differences in the LPC pathway between adults with neovascular AMD and
geographic atrophy.
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Background
Age-related macular degeneration (AMD) is a leading
cause of irreversible visual loss among older adults in
developed countries [1]. Altered lipid metabolism is
implicated in the pathogenesis of AMD. Lipid pathway
genes, dietary lipid intake, and elevated high-density
lipoprotein (HDL) are associated with increased risk of
AMD [2]. AMD is characterized by early deposition of
lipids in Bruch’s membrane and by drusen, focal
deposits of extracellular debris composed of lipids [2].
Whether lipid abnormalities characteristic of AMD
might be associated with alterations in systemic lipids
is not well understood [2].
Lipids are the dominant biologic molecules in human
serum, but relatively less is known about lipids because
of their structural diversity and large number of species
[3]. Recent advances in liquid chromatography-tandem
mass spectrometry (LC-MS/MS) are facilitating new ap-
proaches towards revealing biomarkers and pathways as-
sociated with AMD [4]. We hypothesized that altered
serum lipid concentrations are present in adults with
late AMD. To address this hypothesis, we measured
serum lipids in adults with and without late AMD using
a lipidomics approach and LC-MS/MS.
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Methods
The Age, Gene/Environment Susceptibility Reykjavik
Study (AGES) is a population-based study [5] that in-
cluded AMD assessment, as described elsewhere [6]. Of
5764 adults examined in AGES (2002–2006), AMD sta-
tus was determined in 5272 participants using fundus
photography [6]. Retinal images were evaluated using
the modified Wisconsin Age-related Maculopathy Grad-
ing System [6]. Of 5272 adults with AMD grading avail-
able, 3838 had no AMD, 1123 had early AMD, 133 had
geographic atrophy (GA), and 178 had neovascular
AMD. Simple random sampling was used to select 80
adults with no AMD, 80 with GA, and 80 with neovas-
cular AMD.
Fasting venous blood was drawn, processed, and fro-
zen at − 80 °C. Preanalytical studies show excellent
long-term stability of serum lipids [7–9]. The Lipidyzer™
(Sciex, Framingham, MA) platform [10, 11] was used to
measure lipids in the phosphatidylcholine (PC), phos-
phatidylethanolamine (PE), lysophosphatidylcholine
(LPC), lysophosphatidylethanolamine (LPE), free fatty
acid (FFA), sphingomyelin (SM), diacylglycerol (DAG),
cholesteryl ester (CE), ceramide (CER), hexosylceramide
(HCER), lactosylceramide (LCER), dihydroceramide
(DCER), and triacylglycerol (TAG) groups of lipids on a
5500 QTrap® (Sciex) mass spectrometer. TAG and FFA
were excluded from the analysis since the platform can-
not differentiate TAG by specific acyl composition and
FFA have poor reproducibility (Semba RD, et al., unpub-
lished). Lipid species were included in the data analyses
if above the limit of quantification in > 90% of the
participants.
Continuous and categorical variables were compared
across the three categories of AMD disease status using
Kruskal-Wallis tests and chi-square tests, respectively.
Serum lipid concentrations were log-transformed to
achieve a normal distribution. A false discovery rate
(FDR) approach was used to correct for multiple testing
[11]. Q-values, the minimum FDR, was considered sig-
nificant if q < 0.05. Univariable and multivariable logistic
regression models were used to compare groups of lipids
and individual lipid species between the three groups.
Covariates with established associations with AMD such
as age, smoking, and body mass index (BMI), and those
associated with AMD in this study, including serum
C-reactive protein (CRP) and chronic kidney disease,
were included in the multivariable models. All analyses
were performed using SAS (v. 9.1.3, SAS Institute, Inc.,
Cary, NC) with a type I error of 0.05 to determine statis-
tical significance.
Results
Characteristics of the study participants are shown in
Table 1. Adults with GA and neovascular AMD were
older (P < 0.0001) and had higher serum CRP concentra-
tions (P = 0.01) and chronic kidney disease (P = 0.01)
compared with controls. There were no significant dif-
ferences between adults with GA or neovascular AMD
and controls by sex, body mass index (BMI), smoking,
total cholesterol, HDL cholesterol, LDL cholesterol,
hypertension, coronary artery disease, or diabetes com-
pared with controls.
A total of 177 serum lipids representing eleven groups
of lipids (CER, HCER, LCER, DCER, CE, DAG, LPC, LPE,
PC, PE, SM) were measured. Total mean serum concen-
trations of lipids in each group, adjusted by covariates, are
shown in Table 2. Total serum LPC were higher in adults
with neovascular AMD compared with GA (P = 0.004).
There were no significant differences in total serum lipids
in the other remaining lipid groups between controls and
those with late AMD. Serum lipid species were compared
between controls and those with GA or neovascular
AMD, respectively. Mean serum lipid concentrations in
controls versus those with GA or neovascular AMD,
adjusted by covariates, are shown in Additional file 1:
Table S1. Serum LPC 18:0 was higher in adults with neo-
vascular AMD compared with GA (P = 0.0002).
Discussion
The present study showed no significant differences in
serum concentrations of lipid species between adults
with either GA or neovascular AMD compared with
those without AMD. These findings suggest that the
serum lipids measured in the present study are not asso-
ciated with either form of late AMD. Whether abnormal
deposits of retinal lipids in AMD is due to altered cellu-
lar lipid metabolism in the retinal pigment epithelium
and neuroretina or from altered systemic lipids has not
been completely clear [2, 12]. The present study does
not support a strong role for altered systemic lipid spe-
cies in the pathogenesis of AMD.
A recent study of 30 adults without AMD, 30 with
early AMD, and 30 with late AMD used LC-MS/MS to
identify circulating metabolites associated with AMD
[4]. Several glycerophospholipid species were signifi-
cantly decreased in AMD compared with controls. How-
ever, we were unable to corroborate these findings and
found no significant differences in serum concentrations
of DAG 18:0–20:4, DAG 18:1–18:1, DAG 18:1–18:2, PC
18:0–18:1, PC 18:2–20:4, and PC 18:0–20:4 in adults
with GA or neovascular AMD, respectively, compared
with controls. The previous study reported significant
differences in these lipids between AMD and controls,
however, the study did not adjust for multiple
comparisons in the analysis involving nearly 700 plasma
metabolites [4].
The present study shows serum LPC are higher in
adults with neovascular AMD compared with GA. In
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the blood, LPC are primarily transported by albumin.
LPC are biologically active lipids that serve as ligands
for specific G protein-coupled signaling receptors and
as precursors to lysophosphatidic acid (LPA), an
intermediate in the biosynthetic pathway of cardioli-
pin [13, 14]. Cardiolipin is an important dimeric
phospholipid found almost exclusively in mitochon-
dria [14]. LPA also has specific receptors involved in
growth, differentiation, and angiogenesis [15]. LPC
pathway may distinguish neovascular AMD from GA
in AMD pathogenesis.
The strengths of this study included the standardized
assessment of AMD status, use of an advanced LC-MS/
MS lipidomics platform, a conservative FDR approach in
the statistical analysis, and comparison of normal con-
trols with 80 adults with GA and 80 adults with neovas-
cular AMD, instead of combining GA and neovascular
AMD as a single category of late AMD as done in previ-
ous studies. The findings from AGES cannot necessarily
be extrapolated to other people at risk of AMD. A limi-
tation is that the study did not include adults with early
AMD and thus does not exclude the possibility that









Geographic atrophy vs no AMD Neovascular AMD vs
no AMD
Geographic atrophy vs neovascular AMD
CE 8.52 (0.04) 8.50 (0.04) 8.54 (0.04) 0.75 0.65 0.37
CER 2.16 (0.05) 2.10 (0.05) 2.11 (0.05) 0.43 0.39 0.75
DAG 3.68 (0.06) 3.67 (0.06) 3.63 (0.06) 0.90 0.52 0.78
DCER 0.41 (0.10) 0.23 (0.09) 0.25 (0.08) 0.20 0.22 0.69
HCER 1.87 (0.06) 1.77 (0.05) 1.83 (0.06) 0.29 0.59 0.38
LCER 2.08 (0.05) 1.94 (0.05) 1.97 (0.05) 0.07 0.29 0.57
LPC 5.67 (0.04) 5.64 (0.04) 5.78 (0.04) 0.61 0.05 0.0043
LPE 2.09 (0.07) 2.01 (0.07) 2.15 (0.06) 0.50 0.41 0.17
PC 7.94 (0.04) 8.00 (0.04) 7.98 (0.04) 0.27 0.65 0.73
PE 4.91 (0.08) 4.99 (0.07) 4.90 (0.07) 0.48 0.49 0.48
SM 6.89 (0.04) 6.92 (0.04) 6.94 (0.04) 0.69 0.46 0.64
1Adjusted by age, sex, smoking, BMI, CRP, and chronic kidney disease
2Log total serum lipids (μmol/L), showing mean (SE)
3Significant with q-value < 0.05
Table 1 Characteristics of 240 participants, ≥66 years, in the AGES-Reykjavik Study.by AMD status
Characteristics1 AMD P
No AMD Geographic Atrophy Neovascular AMD
n = 80 n = 80 n = 80
Age, y 75.0 (5.7) 82.3 (4.4) 81.7 (4.7) < 0.0001
Sex, % women 55.0 60.0 56.3 0.80
Body mass index, kg/m2 27.1 (4.4) 26.5 (4.1) 26.3 (4.2) 0.46
Smoking, % Never/Former 85.0 81.3 76.2 0.15
Current 15.0 12.7 23.8
Total cholesterol, mmol/L 5.6 (1.1) 5.5 (1.0) 5.7 (0.9) 0.50
HDL cholesterol, mmol/L 1.6 (0.5) 1.6 (0.5) 1.6 (0.5) 0.86
LDL cholesterol, mmol/L 3.5 (1.0) 3.4 (0.9) 3.5 (0.9) 0.62
Log C-reactive protein, mg/L 0.5 (1.0) 0.8 (1.1) 1.0 (1.0) 0.01
Hypertension, % 81.3 81.3 77.5 0.79
Coronary artery disease, % 36.4 49.3 42.9 0.31
Diabetes, % 15.0 18.8 7.5 0.11
Chronic kidney disease, % 40.9 45.2 64.3 0.01
1Conversion to SI units as follows: total cholesterol, HDL cholesterol, LDL cholesterol in mg/dL × 0.0259 =mmol/L; C-reactive protein in mg/L × 9.524 = μmol/L
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systemic lipid alterations might occur in the earlier
stages of AMD.
Conclusions
The present study suggests that serum lipids are not as-
sociated with late AMD. Future studies are needed to
determine whether other lipid classes not covered by the
present study might be associated with the prevalence or
progression of AMD.
Additional file
Additional file 1: Table S1. Serum lipids species in adults without AMD
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